Breaking News
October 23, 2018 - Adverse Childhood Experiences Tied to Burnout in BSN Students
October 23, 2018 - High levels of oral disease among elite athletes affecting performance
October 23, 2018 - Study examines effect of immediate vs delayed pushing during labor on delivery outcomes
October 23, 2018 - LU-RRTC to spearhead capacity-building efforts for racial and ethnic populations
October 23, 2018 - Maintenance therapy with olaparib improves progression-free survival in advanced ovarian cancer patients
October 23, 2018 - Organic food may protect against cancers finds study
October 23, 2018 - Interweaving anxiety disorder associated with stuttering remains unrecognized
October 23, 2018 - Knowledge of sex differences in lower urinary tract may help stimulate breakthroughs in diagnosis, management
October 23, 2018 - Common antibodies associated with myocardial infarction
October 23, 2018 - Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy
October 23, 2018 - Brain’s ‘Self-Control’ Center May Be Key to Weight-Loss Success
October 23, 2018 - Prosthetic valve mismatches common in transcatheter valve replacement, ups risk of death
October 23, 2018 - Can virtual reality help people become more compassionate?
October 23, 2018 - Screen time eclipsed outdoor time for most students, shows study
October 23, 2018 - SLU researcher seeks to find solutions for ‘chemo brain’ symptoms and side effects of opioids
October 23, 2018 - Plastics now commonly found in human stools
October 23, 2018 - Zoledronic acid increases disease-free survival in premenopausal women with HR+ early breast cancer
October 23, 2018 - Cancer survivors at risk for heart failure during, after pregnancy
October 23, 2018 - Stanford project brings health education videos to mothers in South Africa
October 23, 2018 - HIV-infected Hispanics at higher risk of developing HPV-related cancers, finds study
October 23, 2018 - Politicians hop aboard ‘Medicare-for-all’ train, destination unknown
October 23, 2018 - Study suggests rising childhood obesity rates as cause for serious hip disease in adolescents
October 23, 2018 - Study highlights existence of barriers to early clinical trial access for adolescents and young adults
October 23, 2018 - Protein sequencing technique could revolutionize biomedical research
October 23, 2018 - Canon Medical to showcase world’s first Ultra-High Resolution CT system at ASTRO 2018
October 23, 2018 - Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
October 23, 2018 - Cancer stem cells use ‘normal’ genes in abnormal ways
October 23, 2018 - Bad Blood: A conversation with investigative reporter John Carreyrou | News Center
October 23, 2018 - As U.S. fertility rates collapse, finger-pointing and blame follow
October 23, 2018 - Researchers develop promising targeted strategy to treat chemo-resistant blood cancer
October 23, 2018 - Pilot clinical trial shows effectiveness of bioelectronic medicine device for lupus
October 23, 2018 - Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
October 23, 2018 - 11th World Stroke Congress examines high stroke impact in low- and middle-income countries
October 22, 2018 - Breast cancer survival could be extended with two new drug combinations
October 22, 2018 - Researchers discover how acne-causing bacteria resist treatment
October 22, 2018 - Cancer trial shows treating the prostate with radiotherapy improves survival
October 22, 2018 - New hope for a drug to treat lymphedema symptoms
October 22, 2018 - Immune-Based Treatment Helps Fight Aggressive Breast Cancer, Study Finds
October 22, 2018 - Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC
October 22, 2018 - Paternal exercise has significant impact on child’s lifelong metabolic health
October 22, 2018 - Targeting specific genomic mutation in breast cancer improves survival
October 22, 2018 - Loss of tumor protein p53 helps cancer cells grow in hostile environment
October 22, 2018 - IDT to demonstrate CRISPR expertise at European-focused events
October 22, 2018 - Breathing through the nose improves memory consolidation
October 22, 2018 - Recreational Marijuana Now Legal in Canada
October 22, 2018 - Scientists reveal drumming helps schoolchildren diagnosed with autism
October 22, 2018 - A stage IV cancer patient discusses what it means to live well with serious illness
October 22, 2018 - In Kids with Autism, Short Questionnaire May Detect GI Disorders
October 22, 2018 - Innovative strategy opens up new avenue of treatment for anthrax infections
October 22, 2018 - Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas
October 22, 2018 - Aspirin may be effective in preventing blood clots after knee replacement
October 22, 2018 - Drug cocktail that increases lifespan discovered
October 22, 2018 - Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting
October 22, 2018 - Study shows potential positive impact of group prenatal care on birth outcomes
October 22, 2018 - Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer
October 22, 2018 - Health Tip: Keep Ticks Away
October 22, 2018 - Obsessive-compulsive disorder – Genetics Home Reference
October 22, 2018 - Researchers find disrupted functional connectivity in cerebellum of adults with HF-ASD
October 22, 2018 - Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors
October 22, 2018 - Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma
October 22, 2018 - Overcoming bottlenecks in early drug discovery with the power of sound
October 22, 2018 - Scientists discover genes that contribute to ADHD development
October 22, 2018 - Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma
October 22, 2018 - FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis
October 22, 2018 - At-home biofeedback therapy effective in relieving difficult-to-treat constipation
October 22, 2018 - Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer
October 22, 2018 - People with periodontal disease less likely to reach healthy blood pressure ranges
October 22, 2018 - Phase III LONSURF study shows progression-free survival in patients with refractory metastatic gastric cancer
October 22, 2018 - Primary care doctors ‘not doing enough’ to curb STDs
October 22, 2018 - Pfizer announces PALOMA-3 trial results in patients with HR+, HER2- metastatic breast cancer
October 22, 2018 - ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress
October 22, 2018 - Study findings could set new standard of care for advanced anal cancer
October 22, 2018 - Erlotinib improves progression-free survival in EGFR mutated NSCLC
October 22, 2018 - Pain, insomnia, and depression often drive osteoarthritis patients to seek medical care
October 22, 2018 - The International Society of Refractive Surgery honors Vivior Chairman with Casebeer Award
October 22, 2018 - Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients
October 22, 2018 - Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC
October 22, 2018 - Vertex gets European CHMP positive opinion for KALYDECO to treat patients with cystic fibrosis
October 22, 2018 - Phase III trial reports positive results with HDAC inhibitor in advanced breast cancer patients
October 22, 2018 - Prostate radiotherapy improves survival in men with low burden of metastatic disease
Genetic testing of prostate tumors could identify likely responders to immunotherapy

Genetic testing of prostate tumors could identify likely responders to immunotherapy

image_pdfDownload PDFimage_print

Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.

Developing a genetic test to pick out these men could speed up the path of immunotherapy into use for prostate cancer patients.

A major clinical trial earlier this month became the first to show that immunotherapy could work in advanced prostate cancer – but only for about 10 per cent of men.

Now the new study, involving scientists at The Institute of Cancer Research, London, has discovered that testing the genetics of prostate tumors could identify the likely responders.

The research, published today (Thursday) in the prestigious journal Cell, found that men whose tumors had a distinct pattern of genetic changes could be much more likely to benefit from immunotherapy than otherwise.

The study was supported by funders including the Prostate Cancer Foundation and Stand Up 2 Cancer.

Scientists at The Institute of Cancer Research (ICR) worked with colleagues at the University of Michigan in the US to analyze tumor DNA collected internationally from 360 men with advanced prostate cancer that had spread.

They found that the tumors of 7 per cent of these men were missing both copies of a gene called CDK12, a trait that was linked with a unique pattern of additional genetic changes.

Tumors with this genetic profile contained a higher number of immune cells than other forms of advanced prostate cancer.

They also had a higher number of protein fragments on their surface, called neoantigens, which flag tumor cells to the immune system. Tumors that are associated with large numbers of immune cells and neoantigens often respond better to immunotherapy, presumably because the immune system has already begun to recognize elements of the cancer as foreign.

In a small pilot clinical study carried out in the US as part of the research, two out of four men with advanced prostate cancer whose tumors had CDK12-linked genetic changes responded remarkably well to the immunotherapy drug pembrolizumab.

It follows the results of a clinical trial led by the ICR and The Royal Marsden NHS Foundation Trust which showed pembrolizumab could benefit a subset of patients with advanced prostate cancer who had run out of existing treatment options.

In the new study, the pattern of genetic changes linked with the missing copies of the CDK12 gene was distinct from other, previously identified genetic subtypes of prostate cancer, making this an entirely separate form of the disease.

If the research can be replicated in larger numbers of patients, it could lead to introduction of a genetic test as a precursor to offering immunotherapy.

In future, CDK12 could also be explored as a genetic weakness that could be targeted by new precision drugs for prostate cancer. Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, said:

“Immunotherapy works for a relatively small group of men with advanced prostate cancer – but when it works, it really works. If we can identify in advance who will benefit, then it should accelerate the passage of immunotherapy into routine use for patients.

“Our new study has revealed a distinct group of men with advanced prostate cancer whose tumors have biological features that could make them likely to respond to immunotherapy drugs such as pembrolizumab.

“We now need larger clinical studies to further study the benefit of immunotherapy in this group of patients. In the future, a genetic test could help pick out men with this particular set of genetic changes, so that they can be considered for immunotherapy.”

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

“Increasing our understanding of the biological and genetic features of cancer is vital in the search for smarter, kinder cancer treatments.

“It’s exciting that this study may have cracked the underlying biology of why only some men with prostate cancer appear to respond well to immunotherapy.

“I look forward to this work being taken forward as soon as possible with the aim of ensuring that some men with prostate cancer can start having the same kinds of benefit from immunotherapy that we are seeing in other tumor types.”

Howard Soule, Ph.D., executive vice president and chief science officer of the Prostate Cancer Foundation, said:

“The identification of CDK12 loss as a possible biomarker for identifying prostate cancer patients who may respond to checkpoint immunotherapy is a hugely significant finding, as researchers have struggled with how to effectively use immunotherapy in prostate cancer for many years.

Source:

https://www.icr.ac.uk/news-archive/gene-testing-could-identify-men-with-prostate-cancer-who-may-benefit-from-immunotherapy

Tagged with:

About author

Related Articles